{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cemiplimab+%28monotherapy%29", "query": { "intervention": "cemiplimab (monotherapy)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cemiplimab+%28monotherapy%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T09:01:45.970Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03871348", "title": "A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Neoplasm" ], "interventions": [ { "name": "SAR441000", "type": "DRUG" }, { "name": "Cemiplimab REGN2810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2019-01-03", "completion_date": "2024-02-21", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Cleveland, Ohio • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03871348" }, { "nct_id": "NCT04543071", "title": "Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Adenocarcinoma of the Pancreas", "Adenocarcinoma" ], "interventions": [ { "name": "Motixafortide", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2020-11-09", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543071" }, { "nct_id": "NCT05669989", "title": "International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Isatuximab intravenous (IV)", "type": "DRUG" }, { "name": "Cemiplimab (SAR439684)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Isatuximab subcutaneous (SC)", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-04-05", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05669989" }, { "nct_id": "NCT05662397", "title": "A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Relapsed Cancer", "Refractory Cancer" ], "interventions": [ { "name": "HST-1011", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "HotSpot Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2023-03-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 8, "location_summary": "Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05662397" }, { "nct_id": "NCT04382898", "title": "PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "BNT112", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 75, "start_date": "2019-12-19", "completion_date": "2024-01-23", "has_results": true, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 5, "location_summary": "Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04382898" }, { "nct_id": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Solid Tumors" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-27", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460456" }, { "nct_id": "NCT05557591", "title": "A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "BNT116", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-04-21", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 9, "location_summary": "Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557591" }, { "nct_id": "NCT06413680", "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Clear-Cell Renal-Cell Carcinoma (ccRCC)", "Advanced Solid Tumors" ], "interventions": [ { "name": "REGN10597", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2024-09-23", "completion_date": "2030-02-03", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06413680" }, { "nct_id": "NCT04291105", "title": "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Head and Neck Squamous Cell Carcinoma", "Colo-rectal Cancer" ], "interventions": [ { "name": "VV1", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vyriad, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2020-04-24", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 9, "location_summary": "Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04291105" }, { "nct_id": "NCT06528769", "title": "Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leiomyosarcoma", "Sarcoma" ], "interventions": [ { "name": "all-trans retinoic acid", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Gabriel Tinoco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2025-09-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-28T09:01:45.970Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06528769" } ] }